Shionogi & Co., Ltd.
Stock Price Chart
2026/11/09 12:01 UpdatedPrice Trend
2026/11/09 12:01 UpdatedPrice & Trading Details
2026/11/09 12:01 UpdatedPRICE
TRADING
Analyst Recommendations 12 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/10/28 | ¥43.61 | ¥25.66 | -41.2% |
| 2026/08/03 | ¥46.90 | ¥114.81 | +144.8% |
| 2026/01/29 | ¥68.45 | ¥87.76 | +28.2% |
| 2025/10/27 | ¥50.55 | ¥51.93 | +2.7% |
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
21.4M | +4.83% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
11.1M | +1.15% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
7.4M | +1.24% | |
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
6.1M | -1.67% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
5.7M | +1.90% | |
|
John Hancock Funds III-International Growth Fund
|
3.5M | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
535.8K | +15.21% |
Dividend History 4Years Growth
Updated 2026/11/08| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥78 | +18.2% |
| 2025 | ¥66 | +16.5% |
| 2024 | ¥57 | +13.3% |
| 2023 | ¥50 | +25.0% |
| 2022 | ¥40 | - |
Financial Performance
2026/11/08 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥335,138M | ¥426,684M | ¥435,081M | ¥438,268M |
| Gross Profit | ¥279,722M | ¥364,437M | ¥377,479M | ¥374,441M |
| Operating Income | ¥110,312M | ¥149,004M | ¥153,312M | ¥156,604M |
| Pretax Income | ¥127,109M | ¥224,832M | ¥204,984M | ¥209,777M |
| Net Income | ¥114,185M | ¥184,965M | ¥162,030M | ¥170,435M |
| EPS | ¥126.21 | ¥207.03 | ¥186.11 | - |
| Operating Margin | 32.92% | 34.92% | 35.24% | 35.73% |
| Balance Sheet | ||||
| Total Assets | ¥1,150,601M | ¥1,311,800M | ¥1,416,918M | ¥1,535,349M |
| Total Equity | ¥975,661M | ¥1,100,046M | ¥1,235,325M | ¥1,361,924M |
| Total Liabilities | ¥174,940M | ¥211,754M | ¥181,593M | ¥173,425M |
| Cash | ¥254,420M | ¥309,224M | ¥358,090M | ¥374,795M |
| Interest-bearing Debt | ¥6,674M | ¥9,411M | ¥11,620M | ¥21,882M |
| Equity Ratio | 84.80% | 83.86% | 87.18% | 88.70% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.02 |
| Cash Flow | ||||
| Operating CF | ¥102,068M | ¥177,867M | ¥154,284M | ¥195,460M |
| Investing CF | -¥96,204M | -¥48,292M | ¥5,922M | -¥116,080M |
| Financing CF | -¥36,615M | -¥84,123M | -¥126,853M | -¥64,908M |
| Free CF | ¥70,504M | ¥140,680M | ¥126,017M | ¥143,357M |
| Efficiency | ||||
| ROE | 11.70% | 16.81% | 13.12% | 12.51% |
| ROA | 9.92% | 14.10% | 11.44% | 11.10% |
Latest IR Information
-
Correction / Numeric Data Correction: "Notice of Revision to Earnings Guidance and Annual Dividend Forecast for the Fiscal Year Ending March 31, 2027 (Dividend Increase)"
Revised upward the consolidated earnings guidance for the fiscal year ending March 31, 2027 (including a dividend increase). Revenue up +2.9% from previous forecast, operating income +4.5%, net income attributable to owners of parent +1.2%, etc. Also includes a revision...
Read more -
Supplementary Materials to Financial Results for the Second Quarter (Interim) of the Fiscal Year Ending March 2027
Supplementary consolidated financial materials for the second quarter of the fiscal year ending March 2027. Revenue was 350.4 hundred million yen (substantial increase YoY), operating income was 115.2 hundred million yen, and quarterly profit was 119.6 hundred million yen. Full-year...
Read more -
Fiscal Year 2026 Q2 (Interim) Financial Results Presentation
For the first half, revenue was 350.4 hundred million yen, operating income was 115.2 hundred million yen, and net income attributable to owners of parent was 119.5 hundred million yen. Full-year forecasts were also revised upward, incorporating the IntraBio acquisition...
Read more -
Shionogi & Co., Ltd. - Q2 Financial Summary [IFRS] (Consolidated)
Announcement of the Q2 (interim) results for the fiscal year ending March 2027. Revenue was 350,377 million yen, operating income was 115,244 million yen, and interim profit attributable to owners of the parent was 119,546 million yen. Annual dividend revised...
Read more -
Notice Regarding Revision (Increase) of Earnings Forecast and Annual Dividend Forecast for the Fiscal Year Ending March 2027
Revised upward the earnings forecast for the fiscal year ending March 2027 and increased the interim dividend to 40 yen, the year-end dividend to 46 yen, and the annual dividend to 86 yen. The dividend increase reflects the results of...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥3,355
Rating Score: 2.27 (Based on 12 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.
